Parkinson's Disease Drug Therapies in the Clinical Trial Pipeline: 2021 Update.

ABSTRACT:

Background

Despite the COVID-19 pandemic, there has been considerable activity in the clinical development of novel and improved drug-based therapies for the neurodegenerative condition of Parkinson's disease (PD) during 2020. The agents that were investigated can be divided into "symptomatic" (alleviating the features of the condition) and "disease modifying" (attempting to address the underlying biology of PD) treatments, ST and DMT respectively, with further categorisation possible based on mechanism of action and class of therapy.

Objective

Our goal in this report was to provide an overview of the pharmacological therapies -both ST and DMT - in clinical trials for PD during 2020-2021, with the aim of creating greater awareness and involvement in the clinical trial proces

SUBMITTER: McFarthing K 

PROVIDER: S-EPMC8461678 | biostudies-literature | 2021

REPOSITORIES: biostudies-literature